A-Labs Capital II Inc.
(TSX-V: ALAB.P) (the
“
Company”) is pleased to announce that it has
entered into a letter of intent dated October 16, 2019 with S.R.P.
Plus Holdings Ltd. (“
VLife”), an Israeli private
corporation. Pursuant to the letter of intent, the Company
and VLife have agreed to a proposed acquisition (the
“
Transaction”) by the Company of 100% of the
outstanding securities of VLife in exchange for common shares of
the Company (“
Company Shares”). The
Transaction is intended to constitute the Company’s Qualifying
Transaction under the policies of the TSX Venture Exchange (the
“
Exchange”).
About VLife
VLife is a private company incorporated under
the laws of Israel. Its primary business line is as a
healthcare-focused commercial real estate and specialty medical
services provider under the global brand of VLife Center. The
commercial real estate segment of VLife’s business model is focused
on managing premium lifestyle medical centers that can be rented
out to medical professionals. In addition, VLIFE operates its own
proprietary pain-management and aesthetics clinics within each of
the VLife Centers. VLIFE currently manages four medical
centers in Israel aiming to provide industry leading standard of
care and is in the process of opening an additional two centers in
in Israel.
Transaction Terms
Pursuant to the letter of intent, the parties
will negotiate a definitive agreement providing for the definitive
terms of the Transaction. Other than certain provisions,
including confidentiality and standstill provisions, the letter of
intent is non-binding and is subject to the entering into of the
definitive agreement.
Pursuant to the letter of intent, the parties
intend to complete a business combination – the structure of which
will be determined after receiving tax, legal and other advice –
whereby the Company will acquire all of the issued and outstanding
shares of VLife from the VLife shareholders in exchange for the
issuance of Company Shares to VLife shareholders based upon an
entity value for VLife of US$30,000,000 and an entity value for the
Company of US$1,000,000, before taking into account the Financing
(as defined below). Accordingly, if the Transaction is
completed, and assuming the completion of the maximum offering
under the Financing at the previously mentioned entity value of
VLife, it is expected that the current shareholders of the Company
will hold approximately 2.4% of the issued and outstanding Company
Shares, the shareholders of VLife will hold approximately 73.2% of
the issued and outstanding Company Shares, and the investors under
the Financing will hold approximately 24.4% of the issued and
outstanding Company Shares, all on a non-diluted basis.
On closing of the Transaction, the business of
the Company will be the global business of VLife, and, therefore,
the Company is expected to operate in the Technology or Diversified
Industries sectors as defined by the TSXV.
Financing
In connection with the Transaction, the Company
or VLife is proposing to conduct a brokered private placement for
gross proceeds of a minimum of US$8,000,000 and a maximum of
US$10,000,000 (the “Financing”).
Further terms of the Financing will be announced in a
subsequent news release.
VLife will pay broker, finder and/or advisory
fees in conjunction with the Transaction and Financing, the details
of which will be disclosed in a subsequent press release and/or the
Filing Statement.
Name Change
On closing of the Transaction, the Company is
proposing to change its name to "VLife (Canada) Ltd." or such other
name as VLife may determine.
Directors and Officers
The following are brief biographies of certain
proposed directors and officers of the Company at Closing.
Information regarding additional directors and officers will be
provided at a later date.
Mr. Shlomo Baranovski, Co-Founder and
President
Mr. Baranovski is the Co-Founder of VLife and
has served as President of VLife since its incorporation in 2014.
Together with his co-founders, he has developed a Proof-of-Concept
(POC) method of building a business unit, optimizing its financial
performance and then replicating it via a scale-up model. For the
past 30 years, Mr. Baranovski has built several businesses based on
the scale-up method, including SB Capital, a real estate business
in North-America built from a POC to hundreds of millions of
dollars value with hundreds of SFR’s, commercial centres, multi
family and constructions with replicated scale-up of over 2,500 SFR
units in over 40 locations, and has also built Beyond Clinics, a
leading aesthetics chain of clinics in Israel, by implementing the
same POC method, scaling the business from a single clinic into a
nation-wide recognised multi-clinic business.
Mr. Golan Sapir, Co-Founder &
CEO
Mr. Sapir is the Co-Founder of VLife and has
served as Chief Executive Officer (CEO) of VLife since its
incorporation in 2014. Mr. Sapir is an accomplished executive
director with over 20 years of experience in senior executive
positions within the Israeli banking and capital markets prior to
co-founding VLife, including CEO of Prisma Mutual Funds with over
$8B under direct management; CMO of Ilanot Discount's Mutual Funds
Management Co. Ltd.; Head of Marketing and member of the Board of
Directors of Discount Mortgage Bank; and Vice President of Sigma
Investment House, an Israeli boutique family office and investment
firm.
Mr. Shmuel Ofnagel – Co-Founder & COO
Mr. Ofnagel is the Co-Founder of VLife and has
served as the Chief Operating Officer (COO) of VLife for the past
two years. Mr. Ofnagel is an experienced entrepreneur, with
considerable expertise in the establishment and scale-up of
real-estate businesses in Europe and Israel from incorporation to
multi-million dollar value. In addition, Mr. Ofnagel is an
experienced investor in the fields of real-estate, high-tech and
medical assets.
Sponsorship
The Company will seek a waiver from the Exchange
to the requirement to engage a sponsor in connection with the
Transaction. If a sponsor is required, the Company will identify a
sponsor and pay the sponsorship fee in cash or Company Shares or a
combination of cash and Company Shares. An agreement with a
sponsor should not be construed as any assurance with respect to
the merits of the Transaction or the likelihood of completion.
Trading Halt
In accordance with Exchange policies, the
Company Shares are currently halted from trading and will remain so
until certain documentation required by the Exchange for the
Transaction can be provided to the Exchange. The Company Shares may
resume trading following the Exchange's review of the required
documentation or the Company Shares may remain halted until
completion of the Transaction.
Conditions to Closing the
Transaction
Closing of the Transaction is conditional upon,
among other things, receipt of all required regulatory, corporate,
and third party approvals, including Exchange approval, the
negotiation and execution of the definitive agreement, satisfactory
due diligence by both the Company and VLife, no material adverse
change having occurred to the assets or share capital of either the
Company or VLife, completion of the Financing, and, if required by
the Exchange, filing of a sponsorship report with the Exchange.
There can be no assurance that the Transaction will be completed on
the terms proposed above or at all.
The Transaction is an Arm’s Length Qualifying
Transaction, as defined in the policies of the Exchange, and is
therefore not ordinarily subject to shareholder approval by the
Company’s shareholders. However, as disclosed in the prospectus of
the Company dated December 17, 2018, if a Target is considered to
be a Portfolio Company of A-Labs Finance and Advisory Ltd., the
Exchange has reserved the right to require Majority of the Minority
Approval for such Qualifying Transaction (as such terms are defined
in the prospectus of the Company dated December 17, 2018). The
Exchange will make such determination regarding Majority of
Minority Approval upon considering the facts once the Target is
identified and transaction terms are identified to the
Exchange.
For further information, please
contact:
Doron Cohen, CEO and Director of the Company
Email: doron@alabs.co
Completion of the transaction is subject to a
number of conditions, including but not limited to, Exchange
acceptance and if applicable pursuant to Exchange Requirements,
majority of the minority shareholder approval. Where applicable,
the transaction cannot close until the required shareholder
approval is obtained. There can be no assurance that the
transaction will be completed as proposed or at all.
Investors are cautioned that, except as
disclosed in the management information circular or filing
statement to be prepared in connection with the transaction, any
information released or received with respect to the transaction
may not be accurate or complete and should not be relied upon.
Trading in the securities of a capital pool company should be
considered highly speculative.
The TSX Venture Exchange has in no way passed
upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Information concerning VLife, including the
proposed directors and officers, has been provided to the Company
by VLife for inclusion in this press release.
THIS PRESS RELEASE, REQUIRED BY APPLICABLE
CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN
OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE
SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES
HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS,
AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S.
PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.
Caution Regarding Forward-Looking
Information
The information in this news release includes
certain information and statements about management’s view of
future events, expectations, plans and prospects that constitute
forward looking statements. These statements are based upon
assumptions that are subject to significant risks and
uncertainties. Forward looking statements in this news release
include, but are not limited to, the closing of the Transaction and
the anticipated benefits of the Transactions, including the
proposed business of the Company after completion of the
Transaction. Because of these risks and uncertainties and as a
result of a variety of factors, including with respect to the
closing of the Transaction and related matters, including the
expected timing for execution of a definitive agreement, the
expected capitalization of the Company after completion of the
Transaction, the Financing and the proposed terms of the Financing,
the change of the Company’s name, certain proposed directors and
officers of the Company after completion of the Transaction, the
timing and receipt of all applicable regulatory, corporate,
shareholder and third party approvals, the anticipated benefits
from the Transaction and the satisfaction of other conditions to
Closing, the actual results, expectations, achievements or
performance may differ materially from those anticipated and
indicated by these forward looking statements. Although the Company
believes that the expectations reflected in forward looking
statements are reasonable, it can give no assurances that the
expectations of any forward looking statement will prove to be
correct. Except as required by law, the Company disclaims any
intention and assumes no obligation to update or revise any forward
looking statements to reflect actual results, whether as a result
of new information, future events, changes in assumptions, changes
in factors affecting such forward looking statements or
otherwise.
A Labs Capital II (TSXV:ALAB.P)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
A Labs Capital II (TSXV:ALAB.P)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024